“ Temple has one of the most active pulmonary research programs in the country. All this research creates deeper levels of care and new hope for our patients with debilitating lung disease.” – GERARD J. CRINER, MD
FROM CYTOKINE SUPPRESSION TO SMARTPHONE REMINDERS —WHAT HELPS THE PATIENT? Lung Research that Reflects Patient Needs Over the past decade, Temple has been a national leader in clinical and basic science research projects related to chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary hypertension, and other serious lung conditions. From analyses of diaphragm function and respiratory muscle recruitment to national studies of new drugs, biologicals, devices, and smartphone-based telemedicine, this team’s wide-angled clinical research agenda reflects the technical competencies as well as the entrepreneurial energies of Temple’s pulmonary faculty. In all this work, Gerard J. Criner, MD, and his pulmonary team have stressed inclusion of patients who reflect the racial/ethnic diversity of the surrounding community. In basic research, Dr. Criner and his team focus on underlying mechanisms of major lung diseases. They possess particular expertise in endothelial cell biology, inflammatory cytokines, mucin expression, and immunoregulatory activity. Many of their studies have drawn correlations between novel biomarkers and disease phenotype, progression, or treatment effects.
HEART | LUNG
13